Cancer in Peru

IARC estimates 77,485 new cancer cases and 36,956 cancer deaths in Peru in 2024; the commonest new cancers are prostate, breast and stomach. This page is assembled automatically from OnCo's data: 144 trials with a site there, 3 institutions and 2 people, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

77,485

all cancers

Deaths

36,956

all cancers

Incidence rate

186.6

per 100,000, age-standardised

Mortality rate

84.2

per 100,000, age-standardised

Cumulative risk

18.2%

of a cancer by age 74

Population

34,217,853

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	8,526	40.7	Prostate cancer
Breast	7,471	37.5	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Stomach	6,625	14.9	Gastric & gastro-oesophageal junction cancer
Colorectum	5,313	12.3	Colorectal cancer
Cervix uteri	4,814	23.7	Cervical cancer
Non-Hodgkin lymphoma	3,972	9.8	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Trachea, bronchus and lung	3,727	8.6	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Thyroid	3,120	8.0	Thyroid cancer
Leukaemia	2,856	8.1	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Liver and intrahepatic bile ducts	2,540	5.9	Hepatocellular carcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Stomach	5,170	11.4	Gastric & gastro-oesophageal junction cancer
Trachea, bronchus and lung	3,100	7.0	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Prostate	2,993	12.4	Prostate cancer
Colorectum	2,823	6.2	Colorectal cancer
Cervix uteri	2,405	11.4	Cervical cancer
Liver and intrahepatic bile ducts	2,370	5.4	Hepatocellular carcinoma
Breast	2,083	10.0	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Leukaemia	1,835	4.9	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Pancreas	1,755	3.9	Pancreatic ductal adenocarcinoma
Non-Hodgkin lymphoma	1,377	3.2	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma

Incidence: method 3a, national mortality estimates applied to model-based mortality-to-incidence ratios (country-specific registry data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Peru”, in South America (Latin America and the Caribbean), High HDI, upper middle income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

144 trials in OnCo · 36 recruiting overall

144 trials

Trial			Lead sponsor
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248	Phase 3	Recruiting	Merck Sharp & Dohme LLC	219	2026-10-07
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729	Phase 3	Recruiting	Merck Sharp & Dohme LLC	241	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737	Phase 3	Recruiting	Merck Sharp & Dohme LLC	298	2026-10-06
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) NCT07060807	Phase 3	Recruiting	Merck Sharp & Dohme LLC	200	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Phase 3	Recruiting	Merck Sharp & Dohme LLC	326	2026-10-06
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558	Phase 3	Recruiting	Merck Sharp & Dohme LLC	165	2026-10-06
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) NCT06979596	Phase 2	Recruiting	Merck Sharp & Dohme LLC	60	2026-10-06
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176	Phase 3	Recruiting	Merck Sharp & Dohme LLC	259	2026-10-06
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354	Phase 3	Recruiting	Merck Sharp & Dohme LLC	281	2026-10-06
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan NCT06952504	Phase 3	Recruiting	Merck Sharp & Dohme LLC	265	2026-10-06
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl NCT06824467	Phase 3	Recruiting	Merck Sharp & Dohme LLC	197	2026-10-06
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287 NCT06422143	Phase 3	Recruiting	Merck Sharp & Dohme LLC	216	2026-10-06
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624	Phase 3	Recruiting	Merck Sharp & Dohme LLC	288	2026-10-06
waveLINE-003 NCT05139017	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	135	2026-10-06
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422	Phase 3	Recruiting	Merck Sharp & Dohme LLC	242	2026-10-02
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) NCT06833073	Phase 2	Recruiting	Merck Sharp & Dohme LLC	89	2026-10-01
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) NCT06996782	Phase 1/2	Recruiting	AstraZeneca	103	2026-10-01
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P NCT07361510	Phase 3	Recruiting	Bristol-Myers Squibb	284	2026-09-30
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) NCT06079671	Phase 3	Recruiting	AstraZeneca	205	2026-09-30
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi NCT05920356	Phase 3	Recruiting	Amgen	420	2026-09-25
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm NCT06312137	Phase 3	Recruiting	Merck Sharp & Dohme LLC	270	2026-09-25
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi NCT06717347	Phase 3	Recruiting	Merck Sharp & Dohme LLC	278	2026-09-25
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P NCT06170788	Phase 3	Recruiting	Merck Sharp & Dohme LLC	220	2026-09-25
BELLWAVE-011 NCT06136559	Phase 3	Recruiting	Merck Sharp & Dohme LLC	203	2026-09-24
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N NCT06627647	Phase 3	Recruiting	AstraZeneca	300	2026-09-23
Pan Tumor Rollover Study NCT03899155	Phase 2	Recruiting	Bristol-Myers Squibb	399	2026-09-23
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s NCT06692738	Phase 3	Recruiting	AstraZeneca	328	2026-09-18
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation NCT06952803	Phase 3	Recruiting	AstraZeneca	346	2026-09-18

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Peru, captured 2026-10-07 to 2026-10-10. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Peru is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

3 institutions

Instituto Nacional de Enfermedades Neoplásicas Liga Peruana contra el Cáncer Oncosalud (AUNA)

2 people

People whose main affiliation in OnCo is an institution or company in Peru.

Francisco Berrospi Espinoza Giuliana Càrdenas Gamarra

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Peru is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Peru's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Peru, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Peru's own sources.

A deep dive for Peru is ranked 24 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/pe.json; every country: /api/v1/countries.json.